Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

Choosing dividend stocks is not only about looking at the yield but also ensuring that the company pays regular dividends, ...